FDA excludes GLP-1 from 503B list

The Food and Drug Administration said on April 30 that it is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, the roster of active ingredients that outsourcing facilities may use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act. (fda.gov) The agency said it tentatively found no clinical need for outsourcing facilities to compound those drugs from bulk substances. The proposal was published in the Federal Register on May 1 and opened for public comment through June 29, 2026. For patients and buyers, the immediate point is procedural but important: this is a proposed exclusion, not yet a final rule. For compounders, it is the FDA’s clearest statement yet that it does not see a basis to keep these three GLP-1 ingredients available for routine 503B bulk compounding once the agency completes the notice-and-comment process. (federalregister.gov) ### What exactly is the 503B bulks list? Section 503B applies to outsourcing facilities, which are larger compounders that can make sterile drugs without patient-specific prescriptions and sell them to hospitals, clinics and other healthcare providers. FDA says those facilities generally may compound from bulk drug substances only if the ingredient appears on the 503B bulks list or if the compounded drug is on the FDA drug shortage list at the time of compounding, distribution and dispensing. (fda.gov) The 503B bulks list is therefore not a catalog of all drugs that may ever be compounded. It is a narrower regulatory pathway for bulk active ingredients. If an ingredient is excluded from that list, outsourcing facilities lose one of the main legal routes for making office-stock compounded versions from raw active pharmaceutical ingredient. (fda.gov) ### Why did the FDA say no to these three GLP-1 ingredients? The FDA said in its April 30 announcement that it was proposing to exclude semaglutide, tirzepatide and liraglutide because it found no clinical need for outsourcing facilities to compound them from bulk substances. In the Federal Register notice, the agency said it had “tentatively” reached that conclusion after evaluating the nominations for inclusion on the 503B bulks list. (fda.gov) The agency’s notice addresses the legal standard for the bulks list, not whether all compounding of GLP-1 drugs disappears in every circumstance. FDA separately said in guidance on compounding and shortages that semaglutide and tirzepatide do not currently appear on the 503B bulks list or on the drug shortage list. (federalregister.gov) ### Does this end all compounded semaglutide and tirzepatide? The April 30 proposal is aimed at large-scale outsourcing-facility compounding from bulk ingredients under 503B. Pharmacy Times said that, if finalized, the move would bar 503B outsourcing facilities from compounding these agents from bulk substances regardless of future market conditions. (fda.gov) That does not mean every compounded GLP-1 product becomes automatically unlawful overnight. Compounding law has separate pathways, including section 503A for state-licensed pharmacies filling patient-specific prescriptions, and FDA’s shortage policies have also affected what compounders could do when branded supply was constrained. The practical effect of the current proposal is to narrow the 503B bulk-compounding channel specifically. (fda.gov) ### Why are semaglutide, tirzepatide and liraglutide grouped together? The May 1 Federal Register notice names all three substances together because they were each nominated for inclusion on the 503B bulks list and FDA evaluated whether there was a clinical need for outsourcing facilities to use them in compounding. The agency said it proposes not to include any of the three. (pharmacytimes.com) Semaglutide and tirzepatide have dominated recent demand in obesity and diabetes care, while liraglutide is an older GLP-1 drug. FDA’s action groups them under the same statutory test for 503B bulk compounding rather than treating them as separate market cases. (fda.gov) ### What happens next, and where can people weigh in? The Federal Register notice published on May 1 says comments are due by June 29, 2026, under docket number FDA-2018-N-3240. FDA said it will consider submitted comments before making a final determination on whether to include or exclude the substances from the 503B bulks list. (federalregister.gov) Any final decision will appear through the FDA’s compounding policy process and related docket materials. Until then, the April 30 announcement and May 1 notice are the agency’s operative public record on semaglutide, tirzepatide and liraglutide under the 503B bulks framework. (federalregister.gov) (fda.gov)